Ocular Therapeutix Inc
OCUL
Company Profile
Business description
Ocular Therapeutix Inc is a biotechnology company that specializes in therapies for diseases and conditions of the eye. The company uses its proprietary hydrogel platform technology to deliver therapeutic agents to the eye. Its pipeline consists of eye medication that aims to overcome the limitations of current eye-drop-based therapies for ophthalmic diseases and conditions. Its pipeline product includes Dextenza, OTX-TIC, OTX-TKI, and OTX-IVT.
Contact
15 Crosby Drive
BedfordMA01730
USAT: +1 781 357-4000
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
267
Stocks News & Analysis
stocks
ASX shares plunge but remain undervalued
Shares drop 17% after guidance is revised but we still see value.
stocks
Ask the analyst: Why have markets shunned APA Group?
Australia's premier gas infrastructure firm used to be a market darling, but its shares have taken a severe de-rating in recent years.
stocks
The 10 best US dividend stocks
These undervalued stocks with reliable dividends are worth considering.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,417.50 | 160.30 | -1.87% |
| CAC 40 | 7,431.04 | 59.24 | -0.79% |
| DAX 40 | 20,214.79 | 102.31 | -0.50% |
| Dow JONES (US) | 41,938.45 | 696.75 | -1.63% |
| FTSE 100 | 8,248.49 | 71.20 | -0.86% |
| HKSE | 18,739.67 | 501.22 | -2.60% |
| NASDAQ | 19,161.63 | 317.25 | -1.63% |
| Nikkei 225 | 39,190.40 | 414.69 | -1.05% |
| NZX 50 Index | 12,793.24 | 150.50 | -1.16% |
| S&P 500 | 5,827.04 | 91.21 | -1.54% |
| S&P/ASX 200 | 8,176.20 | 153.00 | -1.84% |
| SSE Composite Index | 3,155.76 | 12.76 | -0.40% |